Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase 4 Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy

NCT00125723 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00125723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00125723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase 4 Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2004
Completion date
December 31, 2005
Enrollment
2,252 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neutropenia